Skip to main content

Table 4 Adjusted analyses according to type of cancer (AIDS-defining cancer and non-AIDS-defining cancer)

From: Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America

  ADC NADC p (test for interaction)
Covariate HR 95% CI P HR 95% CI P  
Sex    0.08    0.86 0.18
 Female (ref) 1.00    1.00    
 Male 0.67 (0.43–1.05)   1.05 (0.61–1.80)   
Cancer diagnosis relative to cART initiation    0.59    0.94 0.81
 Cancer diagnosis after cART (ref) 1.00    1.00    
 Cancer diagnosis before/at cART initiation/Did not start cART 0.90 (0.60–1.33)   1.03 (0.42–2.52)   
CD4 count (cells/μL) at cancer diagnosis    0.87    0.66 0.23
 100 1.08 (0.75–1.55)   1.09 (0.81–1.46)   
 200 1.04 (0.83–1.32)   1.01 (0.89–1.15)   
 350 (ref) 1.00    1.00    
 500 0.96 (0.79–1.18)   1.05 (0.90–1.22)   
HIV-1 RNA at cancer diagnosis    0.04    0.96 0.81
 Undetectable (ref) 1.00    1.00    
 Detectable (400 copies/mL) 1.83 (1.03–3.24)   0.98 (0.41–2.30)   
Years from HIV diagnosis to cancer diagnosis 1.04 (1.00–1.07) 0.03 1.02 (0.98–1.07) 0.26 0.71
Age at cancer diagnosis (per year) 1.02 (1.01–1.04) 0.005 1.02 (1.00–1.04) 0.12 0.70
  1. The last column provides p-values comparing hazard ratios for ADC vs. NADC using tests for interaction
  2. AIDS-defining cancer (ADC); non-AIDS-defining cancer (NADC)
  3. *= p-value from the model on the full cohort with the type of cancer interacted with the given variable. There were 219 subjects in the NADC cohort and 72 deaths. Similarly, there were 564 subjects in the ADC cohort and 159 deaths